Gebski V - Search Results

1

A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.

Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, Lord S, Friedlander M, Boyle F, Simes RJ. Lee CK, et al. Among authors: gebski v. Breast Cancer Res Treat. 2011 Sep;129(2):467-76. doi: 10.1007/s10549-011-1471-9. Epub 2011 Mar 29. Breast Cancer Res Treat. 2011. PMID: 21445568

2

Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.

Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF. Coates A, et al. Among authors: gebski v. J Clin Oncol. 1992 Dec;10(12):1833-8. doi: 10.1200/JCO.1992.10.12.1833. J Clin Oncol. 1992. PMID: 1453197 Clinical Trial.

3

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH, Byrne M, Harvey V, Gill G. Coates A, et al. Among authors: gebski v. N Engl J Med. 1987 Dec 10;317(24):1490-5. doi: 10.1056/NEJM198712103172402. N Engl J Med. 1987. PMID: 3683485 Clinical Trial.

4

Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation.

Gebski V, McNeil D, Coates A, Forbes J. Gebski V, et al. Stat Med. 1987 Sep;6(6):667-78. doi: 10.1002/sim.4780060604. Stat Med. 1987. PMID: 3685721

5

Dynamic balanced randomization for clinical trials.

Signorini DF, Leung O, Simes RJ, Beller E, Gebski VJ, Callaghan T. Signorini DF, et al. Among authors: gebski vj. Stat Med. 1993 Dec 30;12(24):2343-50. doi: 10.1002/sim.4780122410. Stat Med. 1993. PMID: 8134737

6

Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.

Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M, Coates A. Gill PG, et al. Among authors: gebski v. Ann Oncol. 1993 Nov;4(9):741-4. doi: 10.1093/oxfordjournals.annonc.a058658. Ann Oncol. 1993. PMID: 8280654 Free article. Clinical Trial.

7

On the receiving end. VI. Which dimensions of quality-of-life scores carry prognostic information?

Coates A, Gebski V. Coates A, et al. Among authors: gebski v. Cancer Treat Rev. 1996 Jan;22 Suppl A:63-7. doi: 10.1016/s0305-7372(96)90065-1. Cancer Treat Rev. 1996. PMID: 8625351 No abstract available.

8

Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.

Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J. Byrne MJ, et al. Among authors: gebski v. J Clin Oncol. 1997 Sep;15(9):3141-8. doi: 10.1200/JCO.1997.15.9.3141. J Clin Oncol. 1997. PMID: 9294477 Clinical Trial.

9

Quality of life studies of the Australian New Zealand Breast Cancer Trials Group: approaches to missing data.

Coates A, Gebski V. Coates A, et al. Among authors: gebski v. Stat Med. 1998 Mar 15-Apr 15;17(5-7):533-40. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<533::aid-sim800>3.0.co;2-y. Stat Med. 1998. PMID: 9549802

10

Practical approaches to minimize problems with missing quality of life data.

Simes RJ, Greatorex V, Gebski VJ. Simes RJ, et al. Among authors: gebski vj. Stat Med. 1998 Mar 15-Apr 15;17(5-7):725-37. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<725::aid-sim817>3.0.co;2-1. Stat Med. 1998. PMID: 9549819 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

418 results

Search Page